Newsroom
Post Market Movers: Dave Ramsey Warns Against Single Stocks, Impact on Dividend Clients
By KlickAnalytics Data Insights | October 2, 2026 08:10PM ET
Key Points
- Dave Ramsey views single stocks as a risky investment
- Retirees relying on dividends may face different risks
- Johnson & Johnson's Innovative Medicine segment showing growth in Q3
- Johnson & Johnson announces positive new data on ICOTYDE® for plaque psoriasis
- ICOTYDE® demonstrates sustained skin clearance for patients
Financial expert Dave Ramsey has long cautioned investors about the risks associated with investing in single stocks, referring to them as a gamble. For retirees who depend on dividends from stocks such as Johnson and Johnson (J&J) to cover their living expenses, the situation presents a different kind of risk. While Ramsey's advice may serve to protect some investors, it could also potentially cost others in unforeseen ways.
In the third quarter, J&J's Innovative Medicine segment is expected to continue its growth trajectory. The company is anticipated to see advancements in oncology and new product launches, which will help counteract the decline caused by biosimilar competition impacting Stelara. This positive outlook indicates potential opportunities for investors in the pharmaceutical giant.
Recent developments from J&J further highlight the company's innovation and commitment to advancing medical treatments. The announcement of new data on ICOTYDE® (icotrokinra) for difficult-to-treat plaque psoriasis has demonstrated remarkable results. The groundbreaking IL-23R targeted oral peptide has shown significant efficacy in providing sustained skin clearance with a favorable safety profile for patients with psoriasis affecting sensitive areas of the body.
The Phase 3 ICONIC-TOTALa study revealed that ICOTYDE® has had a positive impact on high-impact plaque psoriasis (PsO) sites over a two-year period. Remarkably, 60% of patients with scalp psoriasis and 89% with genital psoriasis achieved complete skin clearance at Week 112. This data underscores the potential of ICOTYDE® as a potent first-line systemic therapy for patients with challenging skin conditions.
The combination of caution from financial guru Dave Ramsey, the promising growth outlook for Johnson & Johnson's Innovative Medicine segment, and the groundbreaking advancements in medical treatments highlight the complex relationship between investment strategies and dividend-based income. As investors navigate the volatile landscape of the stock market, weighing the risks and rewards becomes crucial for making informed decisions. With new developments in medical research and innovation, opportunities for both financial growth and breakthrough treatments emerge, shaping the future of investing and healthcare.
About JNJ
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.For more information:
Ask the market a question. Get a calculated answer.
The AI is not a chatbot bolted onto a document store. It calls the same analytics engine that powers every screen on this platform — so what comes back is a number it computed from raw history, with the command that produced it.
86,000+ instruments
Global equities, ETFs, funds, options, FX, commodities, crypto, economics, filings, transcripts and news — one normalised symbol universe with adjusted history.
A real analytics engine
Screening, backtesting, technicals, options analytics, correlations, seasonality and factor models — computed on demand from raw prices, never a stale cache.
It shows its working
Answers arrive with the charts, tables and tool calls behind them, so you can check the number instead of trusting a paraphrase.
Your own documents
Upload filings, decks and research. Ask across them and the answer cites the page it came from.
Agents and workflows
Multi-step research that runs the platform's tools for you — screen, pull the history, compute, compare, then write it up.
MCP, CLI and API
The same command catalogue from Claude, your own agent, a shell or your pipeline. The answer on screen is the answer your job gets at 4am.
You ask
“How does NVDA usually trade through earnings?”
It calls
→ ka.options_expected_move(NVDA)
It answers
NVDA has averaged a 9.2% absolute move on the day after earnings and closed higher 67% of the time. Two in three reactions land between −4.2% and +16.3% — the distribution is skewed right, not symmetric.
Every figure computed live from our own history — not scraped, not summarised.
Or start with